On the other hand, reduced engagement of the inhibitory co-receptors LAG3, a novel immunotherapeutic target in cancer and particularly B lymphomas, or FCRL6, due to decreased expression of its MHC-II ligand, could contribute to explaining the enhancement of anticancer immune responses by ICD. The gene discussed is LAG3; the disease is cancer.